Nuvation Bio Inc. (NUVB) Current Ratio
- Current ratio · latest quarter: Value 8.37×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 8.37× | Current assets / current liabilities. $726.43M ÷ $86.75M ≈ 8.37× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 726.43M USD | Assets, Current |
| Current obligations | 86.75M USD | Liabilities, Current |
| Cash and equivalents | 258.60M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 402.35M USD | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory | 19.90M USD | Inventory, Net |
| Payables | 12.09M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $726.43M | $86.75M | $258.60M | $402.35M | (m) | $19.90M | $12.09M | (m) | 8.37× |
| 2026-03-31 | $591.53M | $79.52M | $125.39M | $408.34M | (m) | $15.84M | $22.43M | (m) | 7.44× |
| 2025-12-31 | $571.52M | $82.23M | $164.09M | $365.13M | (m) | $11.41M | $9.48M | (m) | 6.95× |
| 2025-09-30 | $577.53M | $68.13M | $98.90M | $450.15M | (m) | $5.71M | $15.36M | (m) | 8.48× |
| 2025-06-30 | $623.21M | $66.36M | $247.97M | $359.75M | (m) | $552.00K | $22.42M | (m) | 9.39× |
| 2025-03-31 | $475.57M | $52.77M | $47.98M | $413.70M | (m) | $14.00K | $10.54M | (m) | 9.01× |
| 2024-12-31 | $526.25M | $58.24M | $35.72M | $466.97M | (m) | $0.00 | $6.35M | (m) | 9.04× |
| 2024-09-30 | $564.99M | $59.03M | $30.04M | $519.10M | (m) | (m) | $12.38M | (m) | 9.57× |
| 2024-06-30 | $587.17M | $51.09M | $34.28M | $542.88M | (m) | (m) | $5.21M | (m) | 11.49× |
| 2024-03-31 | $608.05M | $15.76M | $34.51M | $562.47M | (m) | (m) | $2.44M | (m) | 38.58× |
| 2023-12-31 | $616.43M | $13.97M | $42.65M | $568.56M | (m) | (m) | $2.21M | (m) | 44.11× |
| 2023-09-30 | $625.35M | $16.14M | $24.39M | $594.94M | (m) | (m) | $2.37M | (m) | 38.74× |
| 2023-06-30 | $637.23M | $13.41M | $50.06M | $580.84M | (m) | (m) | $2.58M | (m) | 47.51× |
| 2023-03-31 | $652.56M | $12.55M | $30.07M | $616.54M | (m) | (m) | $2.94M | (m) | 51.99× |
| 2022-12-31 | $667.32M | $13.16M | $101.10M | $559.91M | (m) | (m) | $2.14M | (m) | 50.70× |
| 2022-09-30 | $681.39M | $14.01M | $138.69M | $535.25M | (m) | (m) | $3.00M | (m) | 48.63× |
| 2022-06-30 | $714.26M | $21.27M | $102.32M | $601.48M | (m) | (m) | $12.73M | (m) | 33.57× |
| 2022-03-31 | $748.04M | $21.44M | $106.21M | $631.50M | (m) | (m) | $9.67M | (m) | 34.89× |
| 2021-12-31 | $772.07M | $16.93M | $132.42M | $632.97M | (m) | (m) | $3.92M | (m) | 45.62× |
| 2021-09-30 | $796.61M | $13.31M | $344.63M | $447.15M | (m) | (m) | $5.16M | (m) | 59.86× |
| 2021-06-30 | $813.08M | $10.09M | $449.53M | $357.07M | (m) | (m) | $4.50M | (m) | 80.58× |
| 2021-03-31 | $830.87M | $9.99M | $638.90M | $185.81M | (m) | (m) | $6.00M | (m) | 83.19× |
| 2020-12-31 | $220.68M | $6.55M | $29.75M | $186.00M | (m) | (m) | $2.17M | (m) | 33.69× |
| 2020-06-30 | $3.38K | $147.12K | $3.38K | (m) | (m) | (m) | (m) | (m) | 0.02× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |